

The Gene Encoding Protocadherin 9 (*PCDH9*), a Novel Risk Factor for Major Depressive Disorder

Xiao Xiao^{1,5}, Fanfan Zheng^{2,5}, Hong Chang¹, Yina Ma³, Yong-Gang Yao^{1,4}, Xiong-Jian Luo^{1,6} and Ming Li^{*,1,4,6}

¹Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Kunming, Yunnan, China; ²Brainnetome Center, Institute of Automation, Chinese Academy of Sciences, Beijing, China; ³State Key Laboratory of Cognitive Neuroscience and Learning, IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China; ⁴Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, China

Genomic analyses have identified only a handful of robust risk loci for major depressive disorder (MDD). In addition to the published genome-wide significant genes, it is believed that there are undiscovered 'treasures' underlying the current MDD genome-wide association studies (GWASs) and gene expression data sets, and digging into these data will allow better understanding of the illness and development of new therapeutic approaches. For this purpose, we performed a meta-analytic study combining three MDD GWAS data sets (23andMe, CONVERGE, and PGC), and then conducted independent replications of significant loci in two additional samples. The genome-wide significant variants then underwent explorative analyses on MDD-related phenotypes, cognitive function alterations, and gene expression in brains. In the discovery meta-analysis, a previously unidentified single-nucleotide polymorphism (SNP) rs9540720 in the *PCDH9* gene was genome-wide significantly associated with MDD ($p = 1.69 \times 10^{-8}$ in a total of 89 610 cases and 246 603 controls), and the association was further strengthened when additional replication samples were included ($p = 1.20 \times 10^{-8}$ in a total of 136 115 cases and 355 275 controls). The risk SNP was also associated with multiple MDD-related phenotypes and cognitive function impairment in diverse samples. Intriguingly, the risk allele of rs9540720 predicted lower *PCDH9* expression, consistent with the diagnostic analysis results that *PCDH9* mRNA expression levels in the brain and peripheral blood tissues were reduced in MDD patients compared with healthy controls. These convergent lines of evidence suggest that *PCDH9* is likely a novel risk gene for MDD. Our study highlights the necessity and importance of excavating the public data sets to explore risk genes for MDD, and this approach is also applicable to other complex diseases.

Neuropsychopharmacology (2018) **43**, 1128–1137; doi:10.1038/npp.2017.241; published online 1 November 2017

INTRODUCTION

Major depressive disorder (MDD) is a severe and complex mental disorder with a lifetime prevalence of ~15% (Hasin *et al*, 2005), and was estimated to be the second leading cause of disability in the near future (Kessler and Bromet, 2013) by the World Health Organization. The overall heritability of MDD is 31–42% (Sullivan *et al*, 2000), with certain subsets being more heritable (eg, recurrent early-onset MDD) (Levinson, 2006). Although this trait of MDD suggests potential opportunity to understand the disease *via* genetic analyses, such modest heritability has greatly complicated the search for risk or protective genetic loci. This is reflected by the fact that previous candidate gene studies (Bosker *et al*, 2011) and early genome-wide association studies (GWASs) (Kohli *et al*, 2011; Lewis *et al*, 2010; Major Depressive

Disorder Working Group of the Psychiatric GWAS Consortium *et al*, 2013; Muglia *et al*, 2010; Rietschel *et al*, 2010; Shi *et al*, 2011; Wray *et al*, 2012) were unable to identify large numbers of robust MDD genetic variants. Until recently, two landmark MDD GWAS studies named 23andMe (European descent) (Hyde *et al*, 2016) and CONVERGE (Han Chinese population) (Converge consortium, 2015) were published, and have made promising contributions to the understanding of MDD. 23andMe GWAS used the largest sample size so far, and CONVERGE GWAS focused on female subjects with recurrent MDD to reduce phenotypic heterogeneity. These two GWASs successfully discovered 17 (15 by 23andMe and 2 by CONVERGE consortium) genetic loci yielding genome-wide significance (detailed information about the genome-wide significant risk variants is listed in Supplementary Table S1).

Despite the recent achievements, GWAS approaches in MDD so far still seem to be less successful than in other complex diseases such as schizophrenia (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). This is likely because of the aforementioned higher prevalence but lower heritability of MDD compared with other adult psychiatric disorders (such as schizophrenia),

*Correspondence: Professor M Li, Kunming Institute of Zoology, Chinese Academy of Sciences, No. 32 Jiao-Chang Donglu, Kunming, Yunnan 650223, China, Tel: +86 871 65190162, Fax: +86 871 65190162, E-mail: limingkiz@mail.kiz.ac.cn

⁵Co-first authors.

⁶Co-senior authors.

Received 2 August 2017; revised 13 September 2017; accepted 27 September 2017; accepted article preview online 9 October 2017

and more cases are thus required to detect the same number of single-nucleotide polymorphism (SNP) associations (Levinson *et al*, 2014). Therefore, future meta-analyses of diverse genome-wide data with increasing sample sizes are in critical need. Indeed, meta-analysis has become essential in genetic analyses of complex human diseases, and many recent studies in which meta-analyses combine dozens of GWAS data sets have shed light on the genetic architectures of complex diseases such as schizophrenia (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014), Crohn's disease (Franke *et al*, 2010), and type 2 diabetes mellitus (Voight *et al*, 2010). In addition to genome-wide meta-analysis of SNPs, convergent functional genomics approaches have also aided in identification of potential susceptibility genes and molecular mechanisms for psychiatric disorders including schizophrenia (Ayalew *et al*, 2012; Luo *et al*, 2014) and bipolar disorder (Le-Niculescu *et al*, 2007; Ogden *et al*, 2004). Integration of genome-wide meta-analysis of SNPs and convergent functional genomics data is believed to be an efficient strategy in dissecting the genetic and biological basis of complex illnesses.

To date, GWASs of MDD by 23andMe (Hyde *et al*, 2016), CONVERGE (Converge consortium, 2015), and PGC (Psychiatric Genomics Consortium) (Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium *et al*, 2013) consortia have (fully or partially) released their genome-wide results. In addition, many genome-wide gene expression analyses in brain tissues have also shared their data (Colantuoni *et al*, 2011; GTEx Consortium, 2013; Ramasamy *et al*, 2014), and analyses on subjects with MDD are included (Kim and Webster, 2009, 2010). We believe that systemic utilization of these public resources allows identification of novel MDD risk genes, and will provide valuable information that is beneficial for other psychiatric studies. Besides, MDD patients often exhibit certain related phenotypes and impaired cognitive abilities compared with healthy individuals (Souery *et al*, 2007; Taylor Tavares *et al*, 2007), and accumulating data indicate that genetic loci associated with MDD are also related to these phenotypes in humans (Demirkan *et al*, 2011; Schuhmacher *et al*, 2013; Vrijen *et al*, 2015). So far, researchers have released the data and resources of several GWASs on MDD-related phenotypes such as neuroticism and depressive symptoms (Okbay *et al*, 2016a), preschool internalizing problems (Benke *et al*, 2014), anxiety symptoms (Otowa *et al*, 2016), as well as cognitive functions (Benyamin *et al*, 2014; Okbay *et al*, 2016b), providing valuable tools for further analyses on these phenotypes to strengthen the association between the risk SNPs and MDD and also to reveal potential biological mechanisms. In the current study, we conducted integrative analyses using these data to examine the genetic risk of MDD from convergent perspectives (Le-Niculescu *et al*, 2010; Niculescu, 2005; Ogden *et al*, 2004). We discovered a novel SNP rs9540720 in the *PCDH9* gene conferring genome-wide significant risk of MDD, and this SNP was also associated with multiple MDD-related phenotypes and cognitive function alterations. Intriguingly, the risk allele of rs9540720 was associated with reduced expression of *PCDH9*, consistent with the significant downregulation of this gene in the brain and peripheral blood tissue of MDD patients compared with healthy controls. Collectively, our study supports the potential roles

of *PCDH9* in MDD susceptibility, and illustrates an example of comprehensive utilization of public resources to uncover the genetic risk factors of MDD.

MATERIALS AND METHODS

All the protocols and methods used in this study were approved by the institutional review board of the Kunming Institute of Zoology, Chinese Academy of Sciences.

MDD Discovery GWAS Data Set

23andMe GWAS sample. The 23andMe GWAS sample included 75 607 cases with self-declared depression (SDD) and 231 747 controls (Hyde *et al*, 2016). A previous study showed that SDD and clinically assessed MDD were highly correlated ($r=1.00$, $SE=0.20$) on common-variant-associated genetic effect (Zeng *et al*, 2016). We therefore consider SDD as an alternative phenotype for identifying common risk variants associated with MDD. The participating cohort was collected from the customer base of the consumer genetics company 23andMe (Eriksson *et al*, 2010; Hyde *et al*, 2016; Tung *et al*, 2011). Participants provided informed consents and the protocol was approved by an external AAHRPP-accredited institutional review board, Ethical and Independent Review Services. Detailed information of the samples, genotyping methods, and statistical analyses can be found in the original GWAS report (Hyde *et al*, 2016).

CONVERGE GWAS sample. The CONVERGE GWAS consisted of 5303 cases with MDD and 5337 controls (Converge consortium, 2015). Cases were diagnosed using the Composite International Diagnostic Interview (CIDI) (WHO lifetime version 2.1; Chinese version) following DSM-IV criteria. Preexisting records of bipolar disorder, psychosis or mental retardation, as well as drugs or alcohol abuse history before the first depressive episode were applied as excluding criteria. Controls were recruited from patients undergoing minor surgical procedures at the general hospitals or from local community centers. Detailed information of the samples, genotyping methods, and statistical analyses can be found in the original report (Converge consortium, 2015).

PGC GWAS sample. The PGC GWAS included 9240 patients and 9519 controls (Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium *et al*, 2013). Cases had diagnoses of DSM-IV lifetime MDD using structured diagnostic instruments through direct interviews by trained interviewers or clinician-administered DSM-IV checklists. Most samples ascertained cases from clinical sources, and most controls were randomly selected from the population and screened for their lifetime history of MDD. Detailed descriptions of the samples, data quality, genomic controls, and statistical analyses can be found in the original publication (Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium *et al*, 2013).

MDD Replication Data Set

23andMe Replication sample. The 23andMe Replication sample included 45 773 SDD cases and 106 354 controls independent from the discovery cohort (Hyde *et al*, 2016). The protocols and criteria of participants' recruitment of the 23andMe Replication sample were the same as 23andMe GWAS sample, although the subjects were totally independent as previously described (Hyde *et al*, 2016). The 23andMe Replication sample was also used as the validation sample in the original 23andMe MDD GWAS study (Hyde *et al*, 2016).

Chinese MDD sample. This sample contained 732 MDD cases and 2318 controls as previously described (Zhang *et al*, 2014, 2016). All patients were diagnosed with MDD strictly according to the DSM-IV criteria. Standard diagnostic assessments were supplemented with clinical information obtained by a review of medical records and interviews with family informants. Patients were excluded either when they had a lifetime diagnosis of bipolar disorder, schizoaffective disorder, schizophrenia, or another psychotic disorder, or when they were female and were pregnant, planning to become pregnant, or breast-feeding during the study period. Control subjects were recruited from local volunteers without any history of mental disorders. All participants provided written informed consents.

SNP Selection and Statistical Analysis

SNPs highlighted in 23andMe GWAS sample were first subject to replication analyses in CONVERGE and PGC GWAS samples, and meta-analytic study was then conducted combining samples from all three data sets. Significant associations identified through the above meta-analysis were then replicated in the 23andMe Replication sample and Chinese MDD sample. In each sample, logistic regression was applied to test the association between phenotypes and SNP dosages under an additive model, and covariates included sample grouping and principal components reflecting ancestry. For the meta-analysis, we used odds ratio (OR) and standard error (SE) to estimate heterogeneity between individual samples and to calculate the pooled OR and 95% confidence interval (CI). The calculation was conducted using the classical inverse variance weighted methods with PLINK v1.07 (Purcell *et al*, 2007) in consistency with our previous study (Xiao *et al*, 2017). In the current study, we conducted two-tailed tests for discovery analysis and meta-analysis, and applied one-tailed tests for replication analyses as described before (Psychiatric GWAS Consortium Bipolar Disorder Working Group, 2011). A two-tailed p -value $< 5.00 \times 10^{-8}$ was considered genome-wide statistically significant in the combined samples; in the replication sample, a one-tailed p -value < 0.05 was considered nominally significant.

Analyses on MDD-Related Phenotypes

Neuroticism. Neuroticism is commonly defined as the proneness to negative emotions (including irritability, anger, sadness, anxiety, worry, hostility, self-consciousness, and vulnerability) usually in response to stress-inducing events

(Kotov *et al*, 2010; Lahey, 2009). Neuroticism is a pervasive risk factor for different psychiatric conditions including MDD and entailed emotional dysregulation (Fanous and Kendler, 2004; Kotov *et al*, 2010). The neuroticism data ($n=170\,911$) were obtained from a previous GWAS by Okbay *et al* (2016a). Detailed information of the samples, genotyping methods, and statistical analyses can be found in the original report (Okbay *et al*, 2016a).

Depressive symptoms (DS). The DS data ($n=180\,866$) were retrieved from a previous GWAS by Okbay *et al* (2016a). The authors analyzed the summary statistics from a GWAS of MDD (Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium *et al*, 2013) performed by the PGC (9240 cases and 9519 controls) in combination with data from two additional cohorts: the UKB (105 739 subjects) and the Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort (7231 cases and 49 137 controls). Details on the samples, genotyping methods, and statistical analyses can be found in the original report (Okbay *et al*, 2016a).

Preschool internalizing problems (INTs). INTs are heritable traits with moderate genetic stability from childhood into adulthood, and are found to be highly prevalent in the offspring of MDD patients (Olino *et al*, 2008). The INT data ($n=4596$) were taken from a previous GWAS by Benke *et al* (2014). They investigated the effects of SNPs on INT in a total of 4596 children (3 cohorts) with the Child Behavior Checklist (CBCL). Of the 36 items for INT scale in the most recent version of the CBCL 11/2 – 5, 34 were measured in all 3 cohorts. Example items include 'Acts too young for age,' 'Worries a lot,' and 'Clings to adults or too dependent.' For each item, the rater selected a score of 0 (not true), 1 (somewhat or sometimes true), or 2 (very true or often true), resulting in a potential score range of 0 to 68 for each child. Detailed information of the samples, genotyping methods, and statistical analyses can be found in the original study (Benke *et al*, 2014).

Anxiety phenotype. Anxiety disorders (ADs), namely generalized AD (GAD), panic disorder (PD), and phobias, are relatively common and often disabling conditions with the lifetime prevalence of over 20% (Kessler *et al*, 2005). The anxiety data ($n=15\,299$) were from a previous GWAS by Otowa *et al* (2016). The anxiety phenotype was diagnosed based on DSM with some exceptions, and assessed using quantitative phenotypic factor scores (FSs) derived from a multivariate analysis combining information across the clinical phenotypes. Detailed information of the samples, genotyping methods, and statistical analyses can be found in the original paper (Otowa *et al*, 2016).

Analyses on Cognitive Function

Educational attainment. We used educational attainment as a 'proxy phenotype' for cognitive function. Although educational attainment is not a direct cognitive measure, it is correlated with cognitive ability ($r \sim 0.5$) as well as personality traits related to persistence and self-discipline (Rietveld *et al*, 2013). Educational attainment is strongly associated

with social outcomes, and there is a well-documented health-education gradient. It was estimated that ~40% of the variance in educational attainment is explained by genetic factors (Rietveld *et al*, 2013). For analysis of this phenotype, we used the data from a recent GWAS performed in 293 723 European individuals in whom education attainment was quantified with the well-characterized measurement 'Edu-Years' (an individual's years of schooling) (Okbay *et al*, 2016b). Briefly, educational attainment was measured at an age at which participants were very likely to have completed their education (>95% of the samples were at least 30 years old). On average, participants had 13.3 years of schooling, and 23.1% had a College degree. Details on the samples, genotyping methods, and statistical analyses can be found in the original report (Okbay *et al*, 2016b).

Childhood intelligence. Intelligence, a quantifiable index of cognition, has been widely used in relevant genetic analyses given its great heritability and genetic stability, both in an individual's life course and across generations (Deary *et al*, 2009). Moreover, childhood intelligence is a strong predictor of many important life outcomes including educational attainment (Deary, 2012), and is also associated with various psychiatric disorders such as schizophrenia and MDD (Batty *et al*, 2005; Koenen *et al*, 2009). As a result, we focused on the childhood intelligence phenotype measured with psychometric cognitive tests (Intelligence Quotient (IQ)-type tests). We utilized a recent GWAS of childhood intelligence including 12 441 children of European ancestry (Benyamin *et al*, 2014). In brief, the age of the participants ranged between 6 and 18 years. The best available measure of general cognitive ability (*g*) or intelligence quotient (IQ) derived from diverse tests assessing both verbal and nonverbal ability was used. Detailed information of the cohorts, intelligence measurements, genotyping methods, and statistical analyses can be found in the original study (Benyamin *et al*, 2014).

Healthy Subjects for Expression Quantitative Trait Loci (eQTL) Analysis

To identify the impact of MDD risk SNPs on mRNA expression, we utilized the well-characterized gene expression database BrainCloud (<http://braincloud.jhmi.edu/>) (Colantuoni *et al*, 2011). BrainCloud presents data regarding gene expression regulation in the human brain that guides functional studies of disease-associated variants. The BrainCloud sample comprises 261 postmortem dorsolateral prefrontal cortex (DLPFC) tissues of nonpsychiatric individuals, including 113 Caucasian subjects and 148 African-American individuals at various ages across the lifespan. As *PCDH9* is differentially expressed across different age groups, we retrieved the genotype and expression data of 152 adult individuals (age >18 years; 64 Caucasians and 88 African Americans) from BrainCloud. The statistical analysis was conducted using linear regression, with RNA integrity number (RIN), sex, race, brain PH, postmortem interval (PMI), and age as covariates.

Diagnostic Analysis of *PCDH9* Expression between Patients with MDD and Healthy Controls

We obtained the microarray mRNA expression data of the frontal cortex from 103 adult controls (age >18 years) and

131 adult MDD patients of European ancestry from dbGaP (accession number: phs000979.v1.p1). For the expression data, log₂ ratios were normalized across mean log₂ fluorescent intensities using loess correction (Colantuoni *et al*, 2002). After normalization, surrogate variable analysis (SVA) was conducted on the log₂ ratios to optimize the signal/noise ratio and minimize potential impact from known and unknown sources of systematic confounders (Leek and Storey, 2007). The above data analyses were conducted using R with codes and tools retrieved from the Bioconductor project (<http://www.bioconductor.org/>).

We also collected hippocampal RNA-sequencing (RNA-seq) data of 15 adult MDD cases and 15 adult controls from the Stanley Medical Research Institute (SMRI) data set (<http://sncid.stanleyresearch.org/>) in the FASTQ file format. The RNA-seq reads underwent adaptation and low-quality filtering using btrim64 (Kong, 2011), and were then aligned to human reference genome (Human GRCh38 (hg38), <http://asia.ensembl.org/index.html>) using splice-read mapper (Tophat2 v2.0.14) (Kim *et al*, 2013). The map of known transcripts extracted from Ensembl Build GRCh38. Cufflinks v2.2.1 (Trapnell *et al*, 2012) was applied to call new transcripts as well as to assemble and quantify both the novel and known transcripts with default parameters. For each subject, accepted hits bam files from Tophat2 alignment were merged by Samtools v0.1.18 (Li *et al*, 2009) for the following Cufflinks quantification: (1) reads that were uniquely mapped to genes were used to calculate the gene expression level; (2) to quantify mRNA expression, FPKM (Fragments per Kilobase per Million mapped reads) was calculated to measure the gene-level expression according to the formula $FPKM = F \times 10^3 / L \times 10^6 / N$ (F is the number of fragments mapping to the gene annotation, L is the length of the gene structure in nucleotides, and N is the total number of sequence reads mapped to the genome).

Statistical analyses of mRNA expression associated with diagnosis were conducted in R 3.0.1 using an analyses of covariance (ANCOVA) model. The diagnostic status was applied as independent variables, whereas age, sex, RIN, brain pH, and PMI were set as covariates.

RESULTS

Rs9540720 in *PCDH9* Shows Genome-Wide Significant Association with MDD

In this study, the top 10 000 most significant SNPs (two-tailed $p \leq 5.31 \times 10^{-5}$) in the 23andMe GWAS (Hyde *et al*, 2016), which contained the largest sample size, were first subject to replication analyses in the CONVERGE and PGC GWAS data sets (Converge consortium, 2015; Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium *et al*, 2013). Briefly, SNPs meeting the following criteria were collected for further analyses: (1) the SNPs showed a one-tailed p -value <0.05 in both CONVERGE and PGC GWAS data sets (Converge consortium, 2015; Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium *et al*, 2013), and (2) the SNPs showed the same direction of allelic effects across all three GWAS data sets (Converge consortium, 2015; Hyde *et al*, 2016; Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium *et al*, 2013). This

Table 1 Association of 33 SNPs with Major Depressive Disorder

SNP	CHR	POS	Location	A1	A2	Frequency_A1		23andMe		CONVERGE		PGC		Meta-analysis			
						EUR	CHI	OR	P-value	OR	P-value	OR	P-value	OR	P-value	Q-value	I ²
rs12127723	I	73141767	Intergenic	A	G	0.539	0.163	1.029	4.04E-06	1.091	4.68E-03	1.051	1.25E-02	1.032	9.63E-08	0.207	36.6
rs12145482	I	73227348	Intergenic	G	A	0.540	0.157	1.028	6.35E-06	1.093	3.80E-03	1.056	7.10E-03	1.031	1.29E-07	0.141	49.0
rs1525986	I	73237902	Intergenic	T	C	0.539	0.156	1.027	1.02E-05	1.087	5.73E-03	1.056	6.68E-03	1.030	1.70E-07	0.164	44.7
rs1358041	I	73241582	Intergenic	C	G	0.539	0.156	1.027	1.06E-05	1.087	5.74E-03	1.056	6.69E-03	1.030	1.85E-07	0.163	45.0
rs1358042	I	73241894	Intergenic	C	G	0.539	0.156	1.027	1.06E-05	1.087	5.74E-03	1.056	6.60E-03	1.030	1.85E-07	0.163	45.0
rs11210056	I	73242477	Intergenic	G	T	0.539	0.156	1.027	1.06E-05	1.088	5.31E-03	1.056	6.39E-03	1.030	1.77E-07	0.154	47.0
rs7549440	I	73244475	Intergenic	C	T	0.539	0.156	1.027	1.07E-05	1.088	5.31E-03	1.056	6.48E-03	1.030	1.78E-07	0.155	46.4
rs12117265	I	73251154	Intergenic	A	G	0.539	0.156	1.027	1.10E-05	1.089	4.78E-03	1.057	6.35E-03	1.030	1.67E-07	0.144	48.4
rs4116074	I	73256388	Intergenic	G	A	0.539	0.154	1.027	1.07E-05	1.088	5.35E-03	1.057	6.44E-03	1.031	2.24E-07	0.155	46.4
rs10889992	I	73264835	Intergenic	C	T	0.539	0.157	1.027	1.07E-05	1.093	3.52E-03	1.061	3.99E-03	1.031	1.38E-07	0.105	55.7
rs12119161	I	73489496	Intergenic	G	A	0.522	0.150	1.026	2.86E-05	1.079	2.60E-02	1.038	4.56E-02	1.028	2.43E-06	0.357	2.9
rs12138334	I	73551507	Intergenic	A	G	0.522	0.150	1.025	3.80E-05	1.071	4.21E-02	1.038	4.66E-02	1.027	2.86E-06	0.449	0
rs4233103	I	73579799	Intergenic	G	T	0.521	0.150	1.025	3.45E-05	1.075	3.56E-02	1.039	4.18E-02	1.027	2.33E-06	0.393	0
rs4622015	I	73590062	Intergenic	A	G	0.521	0.150	1.026	3.14E-05	1.067	4.83E-02	1.039	3.99E-02	1.027	2.32E-06	0.498	0
rs4582739	I	73602381	Intergenic	T	C	0.520	0.150	1.026	2.28E-05	1.067	4.81E-02	1.040	3.81E-02	1.028	1.58E-06	0.496	0
rs6674404	I	73631632	Intergenic	T	C	0.510	0.150	1.025	5.23E-05	1.067	4.62E-02	1.040	3.62E-02	1.027	4.02E-06	0.465	0
rs12128855	I	73634013	Intergenic	G	A	0.521	0.154	1.026	2.08E-05	1.067	4.63E-02	1.040	3.72E-02	1.028	1.45E-06	0.498	0
rs7996220	I3	66915901	PCDH9	T	A	0.479	0.418	1.027	1.40E-05	1.058	2.24E-02	1.036	4.98E-02	1.029	8.31E-07	0.556	0
rs2875472	I3	66921954	PCDH9	T	A	0.500	0.601	1.030	1.07E-06	1.077	2.96E-03	1.039	3.90E-02	1.033	2.17E-08	0.288	19.8
rs9540720	I3	66922705	PCDH9	G	A	0.500	0.600	1.030	1.07E-06	1.077	3.00E-03	1.041	2.75E-02	1.033	1.69E-08	0.276	22.3
rs9571576	I3	66936133	PCDH9	C	T	0.510	0.607	1.026	1.56E-05	1.077	3.14E-03	1.035	4.95E-02	1.029	3.88E-07	0.234	31.3
rs7319883	I3	66939588	PCDH9	C	T	0.496	0.601	1.029	3.12E-06	1.076	3.54E-03	1.039	3.36E-02	1.031	5.14E-08	0.269	23.8
rs1831972	I3	66939722	PCDH9	A	C	0.496	0.603	1.029	3.21E-06	1.076	3.55E-03	1.040	3.08E-02	1.031	4.93E-08	0.266	24.4
rs9592461	I3	66941792	PCDH9	A	G	0.498	0.696	1.029	1.78E-06	1.081	4.84E-03	1.042	2.50E-02	1.032	2.63E-08	0.247	28.5
rs1444387	I3	66944131	PCDH9	C	T	0.500	0.696	1.030	1.28E-06	1.080	4.92E-03	1.040	2.96E-02	1.032	3.13E-08	0.277	22.2
rs9540728	I3	66944321	PCDH9	C	A	0.496	0.603	1.029	2.96E-06	1.075	3.82E-03	1.041	2.96E-02	1.031	4.50E-08	0.279	21.7
rs1158646	I3	66946304	PCDH9	C	T	0.496	0.603	1.029	3.01E-06	1.075	3.82E-03	1.040	3.32E-02	1.031	5.26E-08	0.282	21.0
rs9540731	I3	66949370	PCDH9	C	T	0.499	0.696	1.029	1.96E-06	1.080	4.93E-03	1.040	3.35E-02	1.032	5.23E-08	0.272	23.1
rs1413573	I3	66951829	PCDH9	A	G	0.496	0.603	1.029	3.23E-06	1.079	2.71E-03	1.041	2.89E-02	1.032	5.93E-08	0.225	33.0
rs9540734	I3	66965411	PCDH9	A	G	0.496	0.608	1.029	2.48E-06	1.058	2.20E-02	1.044	2.03E-02	1.031	5.59E-08	0.516	0
rs166500	I3	66965826	PCDH9	G	A	0.671	0.850	1.027	4.90E-05	1.101	1.78E-02	1.045	2.41E-02	1.029	2.82E-06	0.226	32.8
rs4883777	I3	66974706	PCDH9	T	C	0.606	0.652	1.028	1.13E-05	1.054	3.66E-02	1.043	2.45E-02	1.030	5.20E-07	0.593	0
rs8066520	I7	27376591	PIPOX	A	G	0.150	0.255	1.037	1.18E-05	1.050	4.23E-02	1.055	3.55E-02	1.039	8.13E-07	0.820	0

Abbreviations: EUR, European; CHI, Chinese; CHR, chromosome; OR, odds ratio; POS, position; SNP, single-nucleotide polymorphism. Genome-wide significant *p*-values ($p < 5.00E-08$) were marked in bold.

replication investigation returned a total of 33 SNPs (Table 1).

These 33 SNPs then underwent the meta-analysis using the three GWAS data sets. An intronic SNP rs9540720 in *PCDH9* at 13q21.32, which showed nominal associations with MDD in 23andMe GWAS (two-tailed $p = 1.07 \times 10^{-6}$, OR = 1.030), CONVERGE GWAS (one-tailed $p = 3.00 \times 10^{-3}$, OR = 1.077), and PGC GWAS (one-tailed $p = 2.75 \times 10^{-2}$, OR = 1.041), was genome-wide significantly associated with the illness in the meta-analysis of all three data sets (a total of 89 610 cases and 246 603 controls, two-tailed $p = 1.69 \times 10^{-8}$, OR = 1.033, Table 1). Five SNPs (rs2875472, rs1831972, rs9592461, rs1444387, and rs9540728) in high linkage disequilibrium (LD) with rs9540720 in both European and Chinese

populations also showed genome-wide significance in the meta-analysis (Table 1). A schematic presentation of the *PCDH9* gene and the locations of rs9540720 and other tested SNPs in this gene are shown in Supplementary Figure S1; the LD relationship and haplotype structure of the *PCDH9* risk SNPs in European and Chinese populations are also displayed in Supplementary Figure S1. Intriguingly, rs9540720 was not related to any of the 15 genome-wide significant SNPs previously reported in the 23andMe GWAS study (Hyde *et al*, 2016).

We further investigated the associations of rs9540720 with MDD in the 23andMe Replication sample and the Chinese MDD sample. Intriguingly, rs9540720 was also nominally associated with MDD in both the 23andMe Replication

sample (one-tailed $p = 4.85 \times 10^{-2}$, OR = 1.014) (Hyde *et al*, 2016) and the Han Chinese MDD sample (one-tailed $p = 2.74 \times 10^{-2}$, OR = 1.125). In addition, meta-analysis combining these two replication samples consistently yielded a nominal association between rs9540720 and MDD (one-tailed $p = 2.88 \times 10^{-2}$, OR = 1.016). When all the discovery and replication samples were merged (a total of 136 115 cases and 355 275 controls), the association was further strengthened (two-tailed $p = 1.20 \times 10^{-8}$, OR = 1.027). Although the effect size for rs9540720 (ie, OR = 1.027) was relatively small, it was still similar to the other previously reported GWAS significant SNPs in 23andMe GWAS (OR ranges from 1.028 to 1.051, Supplementary Table S1) (Hyde *et al*, 2016). This observation is likely attributed to the fact that MDD is polygenic with numerous alleles each accounting for a limited share of genetic risk for the illness (Peterson *et al*, 2017).

Taken together, rs9540720 shows significant associations with MDD in both Europeans and Han Chinese, in line with its stable allelic frequency across those two populations (Supplementary Figure S2a), suggesting that it is a possible common risk SNP for MDD among various ethnic groups.

Rs9540720 Is Associated with MDD-Related Phenotypes and Cognitive Functions

Given the strong implication of phenotypes such as neuroticism and depressive symptoms (Okbay *et al*, 2016a), preschool internalizing problems (Benke *et al*, 2014), as well as anxiety (Otowa *et al*, 2016) in MDD patients, we hypothesized that these phenotypes were also associated with rs9540720. We utilized the public GWAS resources on these MDD-related phenotypes, and found that this SNP was nominally associated with neuroticism ($n = 170\,911$, two-tailed $p = 7.84 \times 10^{-3}$), preschool internalizing problems ($n = 4596$, two-tailed $p = 3.94 \times 10^{-2}$), and anxiety scores ($n = 15\,299$, two-tailed $p = 2.18 \times 10^{-2}$), and was also marginally associated with depressive symptoms ($n = 180\,866$, two-tailed $p = 6.12 \times 10^{-2}$). Intriguingly, the rs9540720 risk [G] allele carriers tended to show more vulnerable personality traits (or worse symptoms) compared with protective allele [A] carriers in these series of analyses. It is hypothesized that MDD shares substantial genetic risk components with schizophrenia and bipolar disorder (Ding *et al*, 2015), and patients with these psychiatric disorders sometimes exhibit overlapping symptoms. We therefore assessed the associations of rs9540720 with schizophrenia and bipolar disorder in the large-scale GWAS samples to understand its role in these two illnesses. However, this SNP was not associated with schizophrenia (34 241 cases and 45 604 controls, two-tailed $p = 0.459$) (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014) or bipolar disorder (10 410 cases and 10 700 controls, two-tailed $p = 0.983$) (Ruderfer *et al*, 2014), suggesting that it is likely a MDD-specific risk variant.

Besides MDD-related phenotypes, it is hypothesized that MDD risk-associated SNP may also affect cognitive abilities. To test the influence of rs9540720 on cognitive functions, we utilized public GWAS data sets of educational attainment (Okbay *et al*, 2016b) and childhood intelligence (Benyamin *et al*, 2014), respectively. In this explorative analysis, rs9540720 was significantly associated with educational

attainment (two-tailed $p = 1.09 \times 10^{-2}$) and childhood intelligence (two-tailed $p = 1.20 \times 10^{-4}$). Notably, the MDD risk allele indicated lower education levels and lower scores in standard IQ tests.

Collectively, these data consistently demonstrated negative impact of rs9540720 risk allele on a variety of MDD-related phenotypes and cognitive abilities, further supporting our hypothesis that rs9540720 was a susceptibility SNP for MDD.

Risk Genotypes in rs9540720 and MDD Diagnosis Predict PCDH9 mRNA Expression

The associations of rs9540720 with MDD and related phenotypes in multiple independent samples lend statistical and biological support for the involvement of this genomic locus in the risk of the illness. However, the exact causal variant and underlying molecular mechanisms remained to be determined. This mission is often difficult in genetic association studies because an associated SNP most likely points to a larger region containing numerous correlated variants with a high degree of LD (Li *et al*, 2016). For this reason, we explored the LD between rs9540720 and surrounding SNPs to investigate whether there were SNPs linked with rs9540720. A proxy search for SNPs of LD with rs9540720 was performed on the SNAP website with the European panel from the 1000-Human-Genomes (pilot 1) data set (<http://archive.broadinstitute.org/mpg/snap/ldplot.php>), and returned quite a few SNPs in relatively high LD ($r^2 > 0.80$) with rs9540720 (Supplementary Figure S2b and Supplementary Table S2). Notably, all the rs9540720-linked SNPs were located in the *PCDH9* intron region, and we therefore searched for potential functional SNPs through bioinformatics predictive analyses via synthesizing annotation information of noncoding elements and genomic properties regarding GC content, evolutionary conservation, and so on using the GWAVA data set (http://www.sanger.ac.uk/sanger/StatGen_Gwava) (Ritchie *et al*, 2014). This functional prediction showed that those SNPs in high LD with rs9540720 were unlikely located in the DNA segments binding to transcription factors or histone markers (eg, H3K4me1, H3K4me3, H3K9ac, and H3K27ac) (Supplementary Table S2) (Ritchie *et al*, 2014), and thus we were unable to identify the causative variant without performing further functional assays. However, there was also the possibility that rs9540720 was an eQTL of a specific gene. According to the data presented in Supplementary Figure S2b, there was only *PCDH9* gene within 400 kb around rs9540720 and its LD SNPs, and hence we examined the association between rs9540720 and *PCDH9* expression using data from BrainCloud (Colantuoni *et al*, 2011). Interestingly, the risk SNP rs9540720 was associated with *PCDH9* mRNA expression in human frontal cortex in 152 healthy adult individuals (two-tailed $p = 0.014$, Figure 1a), with the risk allele predicting lower *PCDH9* mRNA levels. In addition, most other MDD risk SNPs in this genomic region (with genotypes available in BrainCloud) were also associated with lower *PCDH9* mRNA expression in the frontal cortex of these subjects (Supplementary Table S3).

To gain further insights into the potential pathophysiological roles of *PCDH9*, we assessed the effects of diagnostic status on *PCDH9* mRNA expression. According to the frontal cortex microarray mRNA expression data from




Figure 1 Risk genotype and diagnosis predict *PCDH9* expression. (a) Association of rs9540720 with *PCDH9* mRNA expression in the 152 adult subjects from frontal cortex in the BrainCloud data set (Colantuoni et al, 2011). Number of individuals: GG, N=24; GA, N=75; AA, N=53. (b) Diagnostic analysis of *PCDH9* expression in adult samples from frontal cortex in dbGaP using microarray data. MDD, major depressive disorder. Number of individuals: MDD, N=131; Control, N=103. (c) Diagnostic analysis of *PCDH9* expression in the frontal cortex and hippocampus of adult samples from Stanley center using RNA-seq data. N=15 in each group.

dbGaP (103 adult controls and 131 adult MDD patients of European ancestry), *PCDH9* expression was significantly decreased in MDD patients than in control subjects (two-tailed $p=0.0007$, Figure 1b). By analyzing the RNA-seq data of frontal cortex and hippocampus tissues from 15 MDD cases and 15 healthy controls from SMRI, we observed a consistent reduction of *PCDH9* expression in MDD patients compared with healthy controls in both the hippocampus (two-tailed $p=0.0086$, Figure 1c) and the frontal cortex (two-tailed $p=0.068$, Figure 1c). In addition, in a previous transcriptome study using peripheral blood from The Netherlands Study of Depression and Anxiety cohort (Jansen et al, 2016), *PCDH9* mRNA expression was also significantly decreased in 882 patients with current MDD vs 331 healthy controls (two-tailed $p=0.00402$, Supplementary Table S2 in the original study (Jansen et al, 2016)). Moreover, our observations were also partly in concordance with another earlier study (Klempner et al, 2009) showing reduced *PCDH9* expression in the DLPFC and inferior frontal gyrus of suicides with MDD compared with healthy controls (Table 2 in their original study). Interestingly, no differences of *PCDH9* expression between nondepressed suicides and healthy controls were reported (Table 2 in their original study) (Klempner et al, 2009). These diagnostic results were consistent with our eQTL analysis results that individuals carrying the MDD risk allele at rs9540720 (and other risk LD SNPs) had lower mRNA levels. Notably, *PCDH9* expression was enriched in brain tissues compared with other organs (Supplementary Figure S3, *PCDH9* expression in brain tissues is marked in yellow box), highlighting its potential role in brain disorders (eg, MDD).

In summary, we have presented convergent and consistent evidence suggesting that *PCDH9* is a MDD susceptibility gene, and the reduced expression of this gene might contribute to the pathogenesis of the illness.

DISCUSSION

MDD is a major complex mental disorder affecting millions of people worldwide. The advent of genetic studies, especially the GWASs, has greatly promoted our understanding of this illness (Ding et al, 2015). Although several promising candidate genes associated with the risk of MDD have been

identified, studies clarifying more genetic risk factors and the underlying mechanisms for this illness are urgently needed. We believe that if a SNP exhibits (at least) nominal associations with a particular illness among multiple individual samples, and presents genome-wide significance in the comprehensive meta-analysis combining all the above samples, it is then very likely to be an authentic disease relevant locus. To this end, we explored several independent GWAS data sets and report that a locus rs9540720 predicting the mRNA expression of *PCDH9* possessed genome-wide significant association with MDD. In addition to showing that rs9540720 was associated with MDD in 23andMe, CONVERGE, and PGC as well as in the combined meta-analysis, we confirmed that the risk allele of this locus was associated with multiple phenotypes related to MDD pathogenesis and cognitive abilities using a series of convergent analyses. Taken one step further, we examined the roles of rs9540720 and *PCDH9* in clinical diagnosis of MDD, and observed a consistent pattern of allelic associations that risk genotype at this SNP was linked to MDD diagnosis and lower *PCDH9* mRNA expression. Although the analyses on MDD-related phenotypes and cognition failed to achieve genome-wide significance, it was unlikely that the risk allele predicted abnormality associated with the illness in each of those independent phenotypes across diverse samples purely by chance. Moreover, expression of the *PCDH9* gene in brain tissues was also in line with the direction of allelic association, indicating that aberrant regulation of *PCDH9* transcription was the likely molecular mechanism underlying the genetic risk conferred by rs9540720 or its LD SNPs. Taken together, *PCDH9* is likely a *bona fide* MDD susceptibility locus.

In addition, one feature of the current study is the utilization of transethnic data that are believed to leverage LD structural differences across various ethnic groups and thus promote the resolution of fine-mapping causal variants (Li et al, 2017; Morris, 2011). In fact, this idea has also been applied in a recent MDD study (using CONVERGE and PGC data sets) (Bigdeli et al, 2017), in which the authors successfully demonstrated a partially shared polygenic basis of the illness between Han Chinese and European populations (the trans-ancestry genetic correlation of lifetime MDD was 0.33, whereas female-only and recurrent MDD yielded

estimates of 0.40 and 0.41, respectively); however, the *PCDH9* region was not highlighted in their study, probably because of the limited sample size (Bigdeli *et al*, 2017). Although some population-specific risk loci may fail to be identified, this strategy warrants higher detection power for complex trait loci. In our study, rs9540720 showed nominal associations with MDD in both Europeans and Asians, in line with its stable allelic frequency across those two populations (Supplementary Figure S2a), suggesting that it is a possible common risk SNP for MDD among various ethnic groups.

The SNP rs9540720 locates on the chromosome 13q21.32, a chromosomal region that was not recognized as a major locus in the few GWASs of MDD (Lewis *et al*, 2010; Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium *et al*, 2013; Muglia *et al*, 2010; Rietschel *et al*, 2010; Shi *et al*, 2011; Wray *et al*, 2012), probably because of the limited sample sizes. Our meta-analysis combining multiple GWASs significantly boosted the sample size for the genetic analyses and successfully detected associations of *PCDH9* SNPs. The *PCDH9* gene encodes protocadherin 9, a protein of the protocadherin family and cadherin superfamily (transmembrane proteins containing cadherin domains). Interestingly, we have recently identified another gene encoding a protein of the same family, *PCDH17* (locates on 13q21.1), to confer risk of MDD and bipolar disorder (Chang *et al*, 2017). Both the short distance between these two genes on the chromosome (~8.57 Mb, but there is no LD between risk SNPs at *PCDH9* and *PCDH17*) and structural similarities shared by their protocadherin protein products suggest potential correlated biological roles. Although the mechanisms by which *PCDH9* contributes to MDD pathogenesis are unclear, *PCDH17* has been demonstrated to significantly affect synaptic development (Chang *et al*, 2017; Hoshina *et al*, 2013). Intriguingly, a recent quantitative analysis of basic mouse behavior uncovered the role of *Pcdh9* in specific cognitive functions required for long-term recognition (Bruining *et al*, 2015). Therefore, the protein encoded by *PCDH9* may also affect signaling at neuronal synaptic junctions (Asahina *et al*, 2012), and further studies investigating this hypothesis are necessary.

In addition to *PCDH9*, we have also observed marginal genome-wide significant associations between MDD and the SNPs in chromosome 1 region in this meta-analysis (lowest SNP rs12127723, $p = 9.63 \times 10^{-8}$, Table 1). Further validation of the risk associations in additional samples is therefore necessary. It should be noted that this chromosome 1 region contains large-scale number of genomic variants that are in high LD with the risk SNPs (eg, rs12127723 and rs12128855) observed here ($r^2 > 0.8$, Supplementary Figure S4), and these risk SNPs may tag one or more potential functional loci that needs to be identified. However, there are no protein-coding genes within this genomic region (Supplementary Figure S4), adding difficulties to further investigations of the molecular mechanisms underlying this potential genetic risk locus.

Although we herein present a comprehensive report of rs9540720 in the risk of MDD, there are certain limitations to be acknowledged. For example, the present analyses are primarily based on publicly available databases, and the full-scale analyses thus depend on the accessibility of the complete data set. In this case, only a selection of 10 000 SNPs are available from the 23andMe data set (Hyde *et al*,

2016), and the current analysis therefore falls short of the data from 23andMe (indicated as well by 1 vs 15 GWAS hits). Although the purpose of a meta-analysis is normally to maximize the power to detect true effects, the maximal power is not available in our study because of this limitation. Further genome-wide meta-analyses are thus necessary to reflect additional risk loci. Another caveat lies in the eQTL analysis utilizing both Europeans and African-American subjects to maximize the statistical power, even though the allelic frequencies of rs9540720 did not differ significantly between these two ethnic groups (A allele, 0.506 in Europeans and 0.602 in African Americans), and the eQTL effect sizes were also similar among different populations. Future eQTL analyses utilizing larger samples of Europeans and Han Chinese are needed to confirm the current observations.

In sum, using the existing GWAS data sets on MDD, MDD-related phenotypes plus cognitive function, as well as databases of brain tissue gene expression, we have identified a novel genome-wide significant MDD risk gene *PCDH9* through a convergent meta-analysis. Although potential concerns remain to be addressed, our study highlights the necessity and importance of excavating the public data sets to explore undiscovered risk genes for MDD and other complex diseases.

FUNDING AND DISCLOSURE

The authors declare no conflict of interest.

ACKNOWLEDGMENTS

This work was supported by grants from the Strategic Priority Research Program of the Chinese Academy of Sciences (Grant No., XDB13000000), CAS Pioneer Hundred Talents Program (to ML), the National Natural Science Foundation of China (81601176 to FZ), the Strategic Priority Research Program (B) of the Chinese Academy of Sciences (XDB02020003 to Y-GY), and the Bureau of Frontier Sciences and Education, Chinese Academy of Sciences (QYZDJ-SSW-SMC005 to Y-GY). The microarray data in MDD sample used for the expression analyses described in this manuscript were obtained from dbGaP accession number phs000979.v1.p1. This research was supported by the Intramural Research Program of the NIMH (NCT00001260, 900142).

REFERENCES

- Asahina H, Masuba A, Hirano S, Yuri K (2012). Distribution of protocadherin 9 protein in the developing mouse nervous system. *Neuroscience* **225**: 88–104.
- Ayalew M, Le-Niculescu H, Levey DF, Jain N, Changala B, Patel SD *et al* (2012). Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. *Mol Psychiatry* **17**: 887–905.
- Batty GD, Mortensen EL, Osler M (2005). Childhood IQ in relation to later psychiatric disorder: evidence from a Danish birth cohort study. *Br J Psychiatry* **187**: 180–181.
- Benke KS, Nivard MG, Velders FP, Walters RK, Pappa I, Scheet PA *et al* (2014). A genome-wide association meta-analysis of

- preschool internalizing problems. *J Am Acad Child Adolesc Psychiatry* 53: 667–676 e667.
- Benyamin B, Pourcain B, Davis OS, Davies G, Hansell NK, Brion MJ et al (2014). Childhood intelligence is heritable, highly polygenic and associated with FBNP1L. *Mol Psychiatry* 19: 253–258.
- Bigdeli TB, Ripke S, Peterson RE, Trzaskowski M, Bacanu SA, Abdellaoui A et al (2017). Genetic effects influencing risk for major depressive disorder in China and Europe. *Transl Psychiatry* 7: e1074.
- Bosker FJ, Hartman CA, Nolte IM, Prins BP, Terpstra P, Posthuma D et al (2011). Poor replication of candidate genes for major depressive disorder using genome-wide association data. *Mol Psychiatry* 16: 516–532.
- Bruining H, Matsui A, Oguro-Ando A, Kahn RS, Van't Spijker HM, Akkermans G et al (2015). Genetic mapping in mice reveals the involvement of Pcdh9 in long-term social and object recognition and sensorimotor development. *Biol Psychiatry* 78: 485–495.
- Chang H, Hoshina N, Zhang C, Ma Y, Cao H, Wang Y et al (2017). The protocadherin 17 gene affects cognition, personality, amygdala structure and function, synapse development and risk of major mood disorders. *Mol Psychiatry*. doi:10.1038/mp.2016.231.
- Colantuoni C, Henry G, Zeger S, Pevsner J (2002). SNOMAD (Standardization and Normalization of MicroArray Data): web-accessible gene expression data analysis. *Bioinformatics* 18: 1540–1541.
- Colantuoni C, Lipska BK, Ye T, Hyde TM, Tao R, Leek JT et al (2011). Temporal dynamics and genetic control of transcription in the human prefrontal cortex. *Nature* 478: 519–523.
- Converge consortium (2015). Sparse whole-genome sequencing identifies two loci for major depressive disorder. *Nature* 523: 588–591.
- Deary IJ (2012). Intelligence. *Annu Rev Psychol* 63: 453–482.
- Deary IJ, Johnson W, Houlihan LM (2009). Genetic foundations of human intelligence. *Hum Genet* 126: 215–232.
- Demirkan A, Penninx BW, Hek K, Wray NR, Amin N, Aulchenko YS et al (2011). Genetic risk profiles for depression and anxiety in adult and elderly cohorts. *Mol Psychiatry* 16: 773–783.
- Ding Y, Chang LC, Wang X, Guilloux JP, Parrish J, Oh H et al (2015). Molecular and genetic characterization of depression: overlap with other psychiatric disorders and aging. *Mol Neuropsychiatry* 1: 1–12.
- Eriksson N, Macpherson JM, Tung JY, Hon LS, Naughton B, Saxonov S et al (2010). Web-based, participant-driven studies yield novel genetic associations for common traits. *PLoS Genet* 6: e1000993.
- Fanous AH, Kendler KS (2004). The genetic relationship of personality to major depression and schizophrenia. *Neurotox Res* 6: 43–50.
- Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T et al (2010). Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. *Nat Genet* 42: 1118–1125.
- GTEX Consortium (2013). The Genotype-Tissue Expression (GTEx) project. *Nat Genet* 45: 580–585.
- Hasin DS, Goodwin RD, Stinson FS, Grant BF (2005). Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. *Arch Gen Psychiatry* 62: 1097–1106.
- Hoshina N, Tanimura A, Yamasaki M, Inoue T, Fukabori R, Kuroda T et al (2013). Protocadherin 17 regulates presynaptic assembly in topographic corticobasal ganglia circuits. *Neuron* 78: 839–854.
- Hyde CL, Nagle MW, Tian C, Chen X, Paciga SA, Wendland JR et al (2016). Identification of 15 genetic loci associated with risk of major depression in individuals of European descent. *Nat Genet* 48: 1031–1036.
- Jansen R, Penninx BW, Madar V, Xia K, Milaneschi Y, Hottenga JJ et al (2016). Gene expression in major depressive disorder. *Mol Psychiatry* 21: 339–347.
- Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 62: 593–602.
- Kessler RC, Bromet EJ (2013). The epidemiology of depression across cultures. *Annu Rev Public Health* 34: 119–138.
- Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL (2013). TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. *Genome Biol* 14: R36.
- Kim S, Webster MJ (2009). Postmortem brain tissue for drug discovery in psychiatric research. *Schizophr Bull* 35: 1031–1033.
- Kim S, Webster MJ (2010). The Stanley neuropathology consortium integrative database: a novel, web-based tool for exploring neuropathological markers in psychiatric disorders and the biological processes associated with abnormalities of those markers. *Neuropsychopharmacology* 35: 473–482.
- Klempner TA, Sequeira A, Canetti L, Lalovic A, Ernst C, French-Mullen J et al (2009). Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of suicides with and without major depression. *Mol Psychiatry* 14: 175–189.
- Koenen KC, Moffitt TE, Roberts AL, Martin LT, Kubzansky L, Harrington H et al (2009). Childhood IQ and adult mental disorders: a test of the cognitive reserve hypothesis. *Am J Psychiatry* 166: 50–57.
- Kohli MA, Lucae S, Saemann PG, Schmidt MV, Demirkan A, Hek K et al (2011). The neuronal transporter gene SLC6A15 confers risk to major depression. *Neuron* 70: 252–265.
- Kong Y (2011). Btrim: a fast, lightweight adapter and quality trimming program for next-generation sequencing technologies. *Genomics* 98: 152–153.
- Kotov R, Gamez W, Schmidt F, Watson D (2010). Linking "big" personality traits to anxiety, depressive, and substance use disorders: a meta-analysis. *Psychol Bull* 136: 768–821.
- Lahey BB (2009). Public health significance of neuroticism. *Am Psychol* 64: 241–256.
- Le-Niculescu H, McFarland MJ, Mamidipalli S, Ogden CA, Kuczenski R, Kurian SM et al (2007). Convergent Functional Genomics of bipolar disorder: from animal model pharmacogenomics to human genetics and biomarkers. *Neurosci Biobehav Rev* 31: 897–903.
- Le-Niculescu H, Patel SD, Niculescu AB (2010). Convergent integration of animal model and human studies of bipolar disorder (manic-depressive illness). *Curr Opin Pharmacol* 10: 594–600.
- Leek JT, Storey JD (2007). Capturing heterogeneity in gene expression studies by surrogate variable analysis. *PLoS Genet* 3: 1724–1735.
- Levinson DF (2006). The genetics of depression: a review. *Biol Psychiatry* 60: 84–92.
- Levinson DF, Mostafavi S, Milaneschi Y, Rivera M, Ripke S, Wray NR et al (2014). Genetic studies of major depressive disorder: why are there no genome-wide association study findings and what can we do about it? *Biol Psychiatry* 76: 510–512.
- Lewis CM, Ng MY, Butler AW, Cohen-Woods S, Uher R, Pirlo K et al (2010). Genome-wide association study of major recurrent depression in the U.K. population. *Am J Psychiatry* 167: 949–957.
- Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N et al (2009). The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25: 2078–2079.
- Li L, Chang H, Peng T, Li M, Xiao X (2017). Evidence of AS3MT^{d2d3}-Associated Variants within 10q24.32-33 in the Genetic Risk of Major Affective Disorders. *Mol Neuropsychiatry* 2: 213–218.

- Li M, Jaffe AE, Straub RE, Tao R, Shin JH, Wang Y *et al* (2016). A human-specific AS3MT isoform and BORCS7 are molecular risk factors in the 10q24.32 schizophrenia-associated locus. *Nat Med* **22**: 649–656.
- Luo XJ, Li M, Huang L, Steinberg S, Mattheisen M, Liang G *et al* (2014). Convergent lines of evidence support CAMKK2 as a schizophrenia susceptibility gene. *Mol Psychiatry* **19**: 774–783.
- Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium, Ripke S, Wray NR, Lewis CM, Hamilton SP, Weissman MM *et al* (2013). A mega-analysis of genome-wide association studies for major depressive disorder. *Mol Psychiatry* **18**: 497–511.
- Morris AP (2011). Transethnic meta-analysis of genomewide association studies. *Genet Epidemiol* **35**: 809–822.
- Muglia P, Tozzi F, Galwey NW, Francks C, Upmanyu R, Kong XQ *et al* (2010). Genome-wide association study of recurrent major depressive disorder in two European case-control cohorts. *Mol Psychiatry* **15**: 589–601.
- Niculescu AB (2005). Genomic studies of mood disorders – the brain as a muscle? *Genome Biol* **6**: 215.
- Ogden CA, Rich ME, Schork NJ, Paulus MP, Geyer MA, Lohr JB *et al* (2004). Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach. *Mol Psychiatry* **9**: 1007–1029.
- Okbay A, Baselmans BM, De Neve JE, Turley P, Nivard MG, Fontana MA *et al* (2016a). Genetic variants associated with subjective well-being, depressive symptoms, and neuroticism identified through genome-wide analyses. *Nat Genet* **48**: 624–633.
- Okbay A, Beauchamp JP, Fontana MA, Lee JJ, Pers TH, Rietveld CA *et al* (2016b). Genome-wide association study identifies 74 loci associated with educational attainment. *Nature* **533**: 539–542.
- Olin TM, Pettit JW, Klein DN, Allen NB, Seeley JR, Lewinsohn PM (2008). Influence of parental and grandparental major depressive disorder on behavior problems in early childhood: a three-generation study. *J Am Acad Child Adolesc Psychiatry* **47**: 53–60.
- Otowa T, Hek K, Lee M, Byrne EM, Mirza SS, Nivard MG *et al* (2016). Meta-analysis of genome-wide association studies of anxiety disorders. *Mol Psychiatry* **21**: 1391–1399.
- Peterson RE, Cai N, Bigdeli TB, Li Y, Reimers M, Nikulova A *et al* (2017). The genetic architecture of major depressive disorder in Han Chinese women. *JAMA Psychiatry* **74**: 162–168.
- Psychiatric GWAS Consortium Bipolar Disorder Working Group (2011). Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. *Nat Genet* **43**: 977–983.
- Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D *et al* (2007). PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* **81**: 559–575.
- Ramasamy A, Trabzuni D, Guelfi S, Varghese V, Smith C, Walker R *et al* (2014). Genetic variability in the regulation of gene expression in ten regions of the human brain. *Nat Neurosci* **17**: 1418–1428.
- Rietschel M, Mattheisen M, Frank J, Treutlein J, Degenhardt F, Breuer R *et al* (2010). Genome-wide association-, replication-, and neuroimaging study implicates HOMER1 in the etiology of major depression. *Biol Psychiatry* **68**: 578–585.
- Rietveld CA, Medland SE, Derringer J, Yang J, Esko T, Martin NW *et al* (2013). GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. *Science* **340**: 1467–1471.
- Ritchie GR, Dunham I, Zeggini E, Flicek P (2014). Functional annotation of noncoding sequence variants. *Nat Methods* **11**: 294–296.
- Ruderfer DM, Fanous AH, Ripke S, McQuillin A, Amdur RLSchizophrenia Working Group of Psychiatric Genomics Consortium *et al* (2014). Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia. *Mol Psychiatry* **19**: 1017–1024.
- Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014). Biological insights from 108 schizophrenia-associated genetic loci. *Nature* **511**: 421–427.
- Schuhmacher A, Lennertz L, Wagner M, Hofels S, Pfeiffer U, Guttenthaler V *et al* (2013). A variant of the neuronal amino acid transporter SLC6A15 is associated with ACTH and cortisol responses and cognitive performance in unipolar depression. *Int J Neuropsychopharmacol* **16**: 83–90.
- Shi J, Potash JB, Knowles JA, Weissman MM, Coryell W, Scheftner WA *et al* (2011). Genome-wide association study of recurrent early-onset major depressive disorder. *Mol Psychiatry* **16**: 193–201.
- Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K *et al* (2007). Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. *J Clin Psychiatry* **68**: 1062–1070.
- Sullivan PF, Neale MC, Kendler KS (2000). Genetic epidemiology of major depression: review and meta-analysis. *Am J Psychiatry* **157**: 1552–1562.
- Taylor Tavares JV, Clark L, Cannon DM, Erickson K, Drevets WC, Sahakian BJ (2007). Distinct profiles of neurocognitive function in unmedicated unipolar depression and bipolar II depression. *Biol Psychiatry* **62**: 917–924.
- Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR *et al* (2012). Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat Protoc* **7**: 562–578.
- Tung JY, Do CB, Hinds DA, Kiefer AK, Macpherson JM, Chowdry AB *et al* (2011). Efficient replication of over 180 genetic associations with self-reported medical data. *PLoS ONE* **6**: e23473.
- Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP *et al* (2010). Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. *Nat Genet* **42**: 579–589.
- Vrijen JN, Tendolkar I, Arias-Vasquez A, Franke B, Schene AH, Fernandez G *et al* (2015). Interaction of the 5-HTTLPR and childhood trauma influences memory bias in healthy individuals. *J Affect Disord* **186**: 83–89.
- Wray NR, Pergadia ML, Blackwood DH, Penninx BW, Gordon SD, Nyholt DR *et al* (2012). Genome-wide association study of major depressive disorder: new results, meta-analysis, and lessons learned. *Mol Psychiatry* **17**: 36–48.
- Xiao X, Yu H, Li J, Wang L, Li L, Chang H *et al* (2017). Further evidence for the association between LRP8 and schizophrenia. *Schizophr Res*. doi:10.1016/j.schres.2017.05.002.
- Zeng Y, Navarro P, Xia C, Amador C, Fernandez-Pujals AM, Thomson PA *et al* (2016). Shared genetics and couple-associated environment are major contributors to the risk of both clinical and self-declared depression. *EBioMedicine* **14**: 161–167.
- Zhang C, Wu Z, Hong W, Wang Z, Peng D, Chen J *et al* (2014). Influence of BCL2 gene in major depression susceptibility and antidepressant treatment outcome. *J Affect Disord* **155**: 288–294.
- Zhang C, Wu Z, Zhao G, Wang F, Fang Y (2016). Identification of IL6 as a susceptibility gene for major depressive disorder. *Sci Rep* **6**: 31264.

Supplementary Information accompanies the paper on the Neuropsychopharmacology website (<http://www.nature.com/npp>)

Table S1. Effect sizes of the genome-wide significant SNPs in 23andMe GWAS and CONVERGE GWAS (discovery stage)

					23andMe GWAS	
SNP	CHR	POS	A1	A2	OR	SE
rs10514299	5	87663610	T	C	1.051	0.007
rs1518395	2	58208074	G	A	1.034	0.0062
rs2179744	22	41621714	A	G	1.038	0.0067
rs11209948	1	72811904	T	G	1.036	0.0063
rs454214	5	88003403	C	T	1.035	0.0061
rs301806	1	8482078	C	T	1.029	0.0061
rs1475120	6	105389953	A	G	1.03	0.0061
rs10786831	10	106614571	A	G	1.031	0.0062
rs12552	13	53625781	A	G	1.045	0.0061
rs6476606	9	37005561	A	G	1.028	0.0063
rs8025231	15	37648402	C	A	1.036	0.0061
rs12065553	1	80793118	G	A	1.034	0.0067
rs1656369	3	158280085	T	A	1.036	0.0065
rs4543289	5	164484948	G	T	1.031	0.0061
rs2125716	12	84941429	A	G	1.038	0.0071
rs2422321	1	73293393	G	A	1.029	0.0061
rs7044150	9	2982931	C	T	1.033	0.0062
					CONVERGE GWAS	
SNP	CHR	POS	A1	A2	OR	SE
rs12415800	10	69624180	A	G	1.164	0.028
rs35936514	10	126244970	C	T	1.192	0.032

Abbreviation

SNP, single nucleotide polymorphism; CHR, chromosome; POS, position; OR, odds ratio; SE, standard error; A1, allele 1; A2, allele 2. OR was calculated according to allele 1.

Table S2. Functional prediction of the PCDH17 SNPs that in high LD ($r^2 > 0.8$) with rs9540720 using GWAVA dataset

CHR	SNP	Position	Distance to rs9540720	r^2 with rs9540720	D' with rs9540720	Region score	TSS score	Unmatched score
13	rs7996220	66,915,901	6804	0.904	1	0.49	0.33	0.15
13	rs9540717	66,917,219	5486	0.904	1	0.28	0.11	0.02
13	rs9540718	66,920,915	1790	1	1	0.38	0.44	0.18
13	rs2875472	66,921,954	751	1	1	0.36	0.15	0.07
13	rs116802299	66,922,541	164	0.96	1	0.31	0.03	0.05
13	rs9540720	66,922,705	0	-	-	0.34	0.07	0.01
13	rs9564313	66,923,687	982	1	1	0.37	0.25	0.15
13	rs1334398	66,930,599	7894	0.823	0.916	0.24	0.15	0.01
13	rs9540724	66,931,094	8389	1	1	0.26	0.08	0.02
13	rs12864905	66,933,167	10462	1	1	0.24	0.21	0.02
13	rs7995375	66,933,412	10707	1	1	0.29	0.19	0.03
13	rs930573	66,934,613	11908	1	1	0.34	0.26	0.11
13	rs9571576	66,936,133	13428	0.922	1	0.3	0.18	0.05
13	rs9571577	66,937,503	14798	1	1	0.28	0.12	0
13	rs9317585	66,938,916	16211	1	1	0.41	0.34	0.09
13	rs7319883	66,939,588	16883	1	1	0.42	0.33	0.07
13	rs1831972	66,939,722	17017	1	1	0.22	0.16	0.01
13	rs9529052	66,940,097	17392	1	1	0.28	0.14	0
13	rs9592461	66,941,792	19087	1	1	0.34	0.34	0.18
13	rs2324888	66,942,287	19582	1	1	0.38	0.32	0.09
13	rs1444387	66,944,131	21426	1	1	0.23	0.17	0.03
13	rs9540728	66,944,321	21616	1	1	0.28	0.11	0.01
13	rs1158646	66,946,304	23599	1	1	0.35	0.09	0.03
13	rs1158647	66,946,317	23612	1	1	0.27	0.11	0.02
13	rs7988498	66,946,477	23772	1	1	0.29	0.19	0.05
13	rs4635220	66,946,721	24016	1	1	0.34	0.16	0.06
13	rs9540729	66,947,124	24419	1	1	0.29	0.04	0.01
13	rs9540731	66,949,370	26665	1	1	0.27	0.27	0.02
13	rs9540732	66,950,570	27865	1	1	0.26	0.07	0.06
13	rs1413573	66,951,829	29124	0.98	1	0.42	0.18	0.08
13	rs9540733	66,954,754	32049	0.904	1	0.39	0.08	0.03
13	rs9529055	66,957,533	34828	1	1	0.34	0.26	0.07
13	rs7983403	66,961,006	38301	0.886	1	0.37	0.19	0.03
13	rs9540734	66,965,411	42706	0.98	1	0.37	0.33	0.08
13	rs9317586	66,966,427	43722	0.98	1	0.37	0.2	0.03

The results include the prediction scores from 3 different versions of the classifier, which are all in the range 0-1 with higher scores indicating variants prec

Average GERP	Average DAF	Average het	GERP	%GC	TSS distance	SS distance	DNase	FAIRE	H2AFZ	H3K27ac	H3K4me1
1.44879	0.00054	0.00072	-1.02	47.5%	37897	18595	-	-	-	-	1
-0.03903	0.00051	0.00067	0.798	32.7%	39215	19913	-	-	-	-	-
-1.23822	0.00055	0.00063	-6.87	46.5%	42911	23609	2	-	-	-	-
0.81144	0.00059	0.00071	0.225	48.5%	43950	24648	1	-	-	-	-
-0.1681	0.00056	0.00061	0.37	35.6%	44537	25235	-	-	-	-	-
-0.24276	0.00057	0.00064	0.495	47.5%	44701	25399	-	-	-	-	-
0.45252	0.00054	0.00063	-3.19	54.5%	45683	26381	-	-	1	1	-
-0.74319	0.00094	0.00108	2.36	31.7%	52595	33293	-	-	-	-	-
-0.51917	0.00094	0.00109	0.22	48.5%	53090	33788	-	-	-	-	-
-0.43414	0.00103	0.00119	2.32	36.6%	55163	35861	-	-	-	-	-
1.08804	0.00103	0.00119	1.6	36.6%	55408	36106	-	-	-	-	-
1.95865	0.00057	0.00066	-0.322	27.7%	56609	37307	-	1	-	-	-
-0.40878	0.00051	0.00054	2.07	23.8%	58129	38827	-	-	-	-	-
-0.37451	0.00058	0.00065	1.09	26.7%	59499	40197	-	-	-	-	-
1.8583	0.00051	0.00057	2.46	40.6%	60912	41610	-	-	-	-	-
1.97884	0.00098	0.00105	2.79	37.6%	61584	42282	2	-	-	-	-
-0.7928	0.00136	0.00152	1.28	30.7%	61718	42416	-	-	-	-	-
-0.78309	0.00091	0.00107	-3.36	22.8%	62093	42791	-	-	-	-	-
-2.4197	0.00092	0.00108	-6.79	39.6%	63788	44486	-	-	-	-	-
-1.02785	0.00193	0.00111	-7.34	20.8%	64283	44981	-	-	-	-	-
-1.08289	0.001	0.00126	-4.47	34.7%	66127	46825	-	-	-	-	-
-0.15702	0.00107	0.0014	-2.22	37.6%	66317	47015	2	1	-	-	-
0.6265	0.00314	0.00211	-1.05	32.7%	68300	48998	-	-	-	-	-
0.65381	0.00314	0.00211	0.241	29.7%	68313	49011	-	-	-	-	-
-0.04154	0.00215	0.0021	2.57	38.6%	68473	49171	1	-	-	-	-
-0.21824	0.00253	0.00255	0.986	35.6%	68717	49415	-	-	-	-	-
-0.39958	0.00097	0.0011	-0.228	28.7%	69120	49818	-	-	-	-	-
-0.67318	0.00049	0.00066	2.86	32.7%	71366	52064	-	-	-	-	-
-0.28941	0.00053	0.00063	0.531	20.8%	72566	53264	-	-	-	-	-
-0.33536	0.00049	0.00056	-0.432	35.6%	73825	54523	1	-	-	-	-
0.06932	0.00055	0.00077	-0.298	63.4%	76750	57448	-	-	-	-	-
1.13258	0.00068	0.00076	-2.48	40.6%	79529	60227	-	-	-	-	-
-0.94489	0.00138	0.00059	-4.13	28.7%	83002	63700	-	-	-	-	-
1.80122	0.00076	0.00096	3.41	32.7%	87407	68105	-	-	-	-	-
-0.76877	0.00049	0.00056	-2.17	29.7%	88423	69121	-	-	-	-	-

dicted as more likely to be functional, and the underlying annotations used to compute these scores.

H3K4me2	H3K4me3	H3K9ac	TRAN	dnase_fps	in_cpg
1	-	-	1	-	-
-	-	-	-	-	-
-	-	-	1	-	-
-	-	-	-	1	-
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	-	2	-
-	-	-	-	-	-
-	-	-	1	-	-
-	-	-	-	-	1
-	-	-	1	-	-
-	-	-	-	-	-
-	-	-	1	-	-
-	-	-	-	-	-
-	-	-	-	1	-
-	-	-	-	2	-
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	-	-	1
-	-	-	-	-	-
-	-	-	2	-	-
-	-	-	2	-	-
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	1	-	-
-	-	-	-	-	-
-	-	-	-	1	1
-	-	-	-	-	-
-	-	-	-	-	1
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	1	-	-

Table S3. Association of MDD risk SNPs with PCDH9 mRNA expression in BrainCloud dataset.

SNP	Estimate	Std. Error	t value	Pr(> t)
rs9540720	0.111056	0.044543	2.4932	1.38E-02
rs9571576	-0.10538	0.046966	-2.24392	2.64E-02
rs1831972	0.136088	0.043408	3.13507	2.08E-03
rs9592461	0.069917	0.04039	1.73104	8.56E-02
rs1444387	-0.08213	0.039501	-2.07922	3.94E-02
rs1158646	-0.13516	0.045502	-2.97054	3.48E-03
rs166500	-0.05462	0.044775	-1.2199	0.224495
rs4883777	0.104724	0.041661	2.51371	1.30E-02

Figure S1. Locations and haplotype block structure of the tested SNPs in PCDH9.
The PCDH9 exons are marked in red. Rs9540720 is highlighted with a red rectangle.






Figure S2. Global distributions of rs9540720 in 53 world populations (a) and plot of chromosome region showing a genomic area of LD with rs9540720 in European populations (b).





Figure S3. Expression of PCDH9 in human tissues according to data from GTEx RNA-seq analysis.




Figure S4. Plot of chromosome region showing a genomic area of LD with rs12127723 and rs12128855 in chromosome 1 region in European populations.

